ABOUT US

KITS

Inflanova is a leader in groundbreaking diagnostic solutions, empowering healthcare professionals to deliver faster, more accurate diagnoses and personalized treatment plans for their patients.
Read More

Vaccines

Harnessing cutting-edge technology and extensive research, our Vaccine represents a paradigm shift in healthcare.
Read More

Precision Medicine

Our solutions enable early and accurate disease detection, allowing for the development of customized treatment plans that address individual needs and optimize health outcomes.
Read More

“Building Immunity,
Building Trust : Vaccines for a
Healthier World”

Inflanova AB is a vaccine development company committed to addressing chronic inflammatory diseases and viral infections through innovative science. Founded by Dr. Shailesh Kumar Samal and Dr. Johan Frostegård, our mission is to transform healthcare with vaccines that go beyond conventional approaches, offering protection against both immediate and long-term health threats.

With a commitment to improving global health, Inflanova AB is at the forefront of vaccine innovation, working to reduce the burden of chronic inflammatory diseases and viral infections, and helping people live healthier, longer lives.

Vision Statement

“Redefining healthcare through pioneering solutions and research excellence, empowering a world where proactive prevention and personalized care lead to healthier, longer lives.”

Mission Statement

“To push the boundaries of scientific discovery, transforming healthcare with cutting-edge innovations and empowering individuals with the tools and knowledge to take charge of their well-being, ultimately creating a future where preventable diseases are minimized, and health is personalized.”

Compuny Founder Details.

Dr. Shailesh Kumar Samal

Co-Founder and CEO, Inflanova AB

Dr. Shailesh Kumar Samal is a leading authority in immunotherapy and biotechnology, with dual Ph.D. degrees in Medical Sciences from Karolinska Institutet and Biochemistry from Maastricht University. As a serial entrepreneur, he has founded and led several biotech companies, including Inflanova AB. Dr. Samal has collaborated with Nobel laureates worldwide and is a nominated member of Sigma Xi, The Scientific Research Honor Society, known for its prestigious membership that includes 200 Nobel laureates. Sigma Xi, founded in 1886, honors excellence in scientific research and fosters collaboration among scientists and engineers. Dr. Samal also serves as an adjunct professor at IIT Ropar, where he is the youngest professor across all IITs. His pioneering work in developing vaccines and diagnostics for chronic inflammatory conditions reflects his deep commitment to advancing science and education.

Prof. Johan Frostegård

Co-Founder and Chairman, Inflanova AB

Prof. Johan Frostegård, a distinguished researcher and physician, leads the Unit of Immunology and Chronic Disease at Karolinska Institutet. His research focuses on the immune system’s role in cardiovascular diseases. Frostegård has co-founded multiple biotech startups, including Inflanova AB, and serves as an advisor to various companies. With a background in economics and medicine, he also writes novels and popular science books, offering insights on humanities and societal issues. His multifaceted contributions continue to influence both science and literature.

Advisory Board

Changing the world is possible.
We’ve done it before.

Join us and make the world a healthier place.
Scroll to Top
Samidha Sathpathy img

Samidha Satpathy

Board Member, Chief Financial Officer, Inflanova AB

Samidha Sathpathy is a seasoned professional with a wealth of experience in finance and audit. Holding a prominent position as Chief Financial Officer and board member, he brings a robust skill set honed through years of dedication and expertise. A graduate of INSEAD, France, Mr. Satpathy’s insights and strategic acumen have been instrumental in driving the financial success of the four companies he is currently associated with. His leadership and comprehensive understanding of financial intricacies make him a valuable asset in navigating complex business landscapes.